Microarray analysis of Dupuytren's disease cells: The profibrogenic role of the TGF-β inducible p38 MAPK pathway

Cellular Physiology and Biochemistry

Volumn 30, Issue 4, 2012, Pages 927-942

  Ratkaj, Ivana ^a   Bujak, Maro ^b   Jurišić, Davor ^c   Loncar, Mirela Baus ^b   Bendelja, Krešo ^d   Pavelić, Krešimir ^a   Pavelić, Sandra Kraljević ^a  

^a University of Rijeka   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

^c KBC RIJEKA   (Croatia)

^d INSTITUTE OF IMMUNOLOGY   (Croatia)

Author keywords

Akt; CD90; Differentiation; Dupuytren's disease; Myofibroblasts; P38

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ALPHA TUBULIN; FIBULIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; MITOGEN ACTIVATED PROTEIN KINASE P38; THROMBOSPONDIN 1; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SUBPOPULATION; CONTROLLED STUDY; DOWN REGULATION; DUPUYTREN CONTRACTURE; EXTRACELLULAR MATRIX; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; INHIBITION KINETICS; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; MYOFIBROBLAST; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STEM CELL; UPREGULATION;

EID: 84865838797     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000341470     Document Type: Article

References (72)

1. Wynn TA: Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007;117:524-529. (Pubitemid 46348506)
2. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
3. Sedic M, Jurisic D, Stanec Z, Hock K, Pavelic K, Kraljevic Pavelic S: Functional genomics in identification of drug targets in Dupuytrens contracture. Front Biosci 2010;15:57-64.
4. Black EM, Blazar PE: Dupuytrens disease: an evolving understanding of an age-old disease. J Am Acad Orthop Surg 2011;19:746-757.
5. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG: Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002;110:341-350. (Pubitemid 34847966)
6. Chilosi M, Poletti V, Zamo A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, Cancellieri A, Maestro R, Semenzato G, Doglioni C: Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003;162:1495-1502. (Pubitemid 36512831)
7. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, Kalluri R: Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007;282:23337-23347. (Pubitemid 47311952)
8. Rygiel KA, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA, Jones DE, Burt AD, Kirby JA: Epithelialmesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest 2008;88:112-123. (Pubitemid 351161272)
9. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, Valerius MT, McMahon AP, Duffield JS: Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010;176:85-97.
10. Shaw RB Jr, Chong AK, Zhang A, Hentz VR, Chang J: Dupuytrens disease: history, diagnosis, and treatment. Plast Reconstr Surg 2007;120:44e-54e.
11. Rayan GM: Dupuytren disease: Anatomy, pathology, presentation, and treatment. J Bone Joint Surg Am 2007;89:189-198.
12. Badalamente MA, Hurst LC: The biochemistry of Dupuytrens disease. Hand Clin 1999;15:35-42, v-vi.
13. Bayat A, Watson JS, Stanley JK, Alansari A, Shah M, Ferguson MW, Ollier WE: Genetic susceptibility in Dupuytrens disease. TGF-beta1 polymorphisms and Dupuytrens disease. J Bone Joint Surg Br 2002;84:211-215.
14. Mattoli S, Bellini A, Schmidt M: The role of a human hematopoietic mesenchymal progenitor in wound healing and fibrotic diseases and implications for therapy. Curr Stem Cell Res Ther 2009;4:266-280.
15. Roderfeld M, Rath T, Voswinckel R, Dierkes C, Dietrich H, Zahner D, Graf J, Roeb E: Bone marrow transplantation demonstrates medullar origin of CD34+ fibrocytes and ameliorates hepatic fibrosis in Abcb4-/-mice. Hepatology 2010;51:267-276.
16. Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S: Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003;171:380-389. (Pubitemid 36745311)
17. Aiba S, Tagami H: Inverse correlation between CD34 expression and proline-4-hydroxylase immunoreactivity on spindle cells noted in hypertrophic scars and keloids. J Cutan Pathol 1997;24:65-69. (Pubitemid 27099860)
18. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, Wilke CA, Toews GB: CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 2005;166:675-684. (Pubitemid 40315625)
19. Barth PJ, Westhoff CC: CD34+ fibrocytes: morphology, histogenesis and function. Curr Stem Cell Res Ther 2007;2:221-227. (Pubitemid 47496606)
20. Naik-Mathuria B, Pilling D, Crawford JR, Gay AN, Smith CW, Gomer RH, Olutoye OO: Serum amyloid P inhibits dermal wound healing. Wound Repair Regen 2008;16:266-273. (Pubitemid 351342135)
21. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM: Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004;114:438-446. (Pubitemid 39071616)
22. Wada T, Sakai N, Matsushima K, Kaneko S: Fibrocytes: a new insight into kidney fibrosis. Kidney Int 2007;72:269-273. (Pubitemid 47172378)
23. Pan D, Watson HK, Swigart C, Thomson JG, Honig SC, Narayan D: Microarray gene analysis and expression profiles of Dupuytrens contracture. Ann Plast Surg 2003;50:618-622. (Pubitemid 36666699)
24. Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF: Comparison of gene expression profiles between Peyronies disease and Dupuytrens contracture. Urology 2004;64:399-404. (Pubitemid 39092491)
25. Satish L, La Framboise WA, O'Gorman DB, Johnson S, Janto B, Gan BS, Baratz ME, Hu FZ, Post JC, Ehrlich GD, Kathyu S: Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytrens Contracture. BMC Med Genomics 2008;1:10.
26. Shih B, Wijeratne D, Armstrong DJ, Lindau T, Day P, Bayat A: Identification of biomarkers in Dupuytrens disease by comparative analysis of fibroblasts versus tissue biopsies in disease-specific phenotypes. J Hand Surg Am 2009;34:124-136.
27. Kraljevic Pavelic S, Bratulic S, Hock K, Jurisic D, Hranjec M, Karminski-Zamola G, Zinic B, Bujak M, Pavelic K: Screening of potential prodrugs on cells derived from Dupuytrens disease patients. Biomed Pharmacother 2009;63:577-585.
28. Tse R, Howard J, Wu Y, Gan BS: Enhanced Dupuytrens disease fibroblast populated collagen lattice contraction is independent of endogenous active TGF-beta2. BMC Musculoskelet Disord 2004;5:41.
29. Pfaffl MW, Horgan GW, Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002;30:e36.
30. Kraljevic Pavelic S, Sedic M, Hock K, Vucinic S, Jurisic D, Gehrig P, Scott M, Schlapbach R, Cacev T, Kapitanovic S, Pavelic K: An integrated proteomics approach for studying the molecular pathogenesis of Dupuytrens disease. J Pathol 2009;217:524-533.
31. Kraljeviæ Paveliæ S, Ratkaj I: Microarray expression analysis of primary Dupuytrens contracture cells; in Eaton C SM, Bayat A, Gabbiani G, Werker P, Wach W (eds): Dupuytrens disease and related hyperproliferative disorders. Berlin, Heidelberg, Springer Verlag, 2012, pp 109-113.
32. Bornstein P: Thrombospondins: structure and regulation of expression. FASEB J 1992;6:3290-3299.
33. Murphy-Ullrich JE, Poczatek M: Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000;11:59-69. (Pubitemid 30169726)
34. Vaughan MB, Howard EW, Tomasek JJ: Transforming growth factor-beta1 promotes the morphological and functional differentiation of the myofibroblast. Exp Cell Res 2000;257:180-189. (Pubitemid 30324656)
35. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA: Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002;3:349-363. (Pubitemid 34619269)
36. Hinz B: Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 2007;127:526-537.
37. Bornstein P: Thrombospondins as matricellular modulators of cell function. J Clin Invest 2001;107:929-934. (Pubitemid 32323400)
38. Donnini S, Morbidelli L, Taraboletti G, Ziche M: ERK1-2 and p38 MAPK regulate MMP/TIMP balance and function in response to thrombospondin-1 fragments in the microvascular endothelium. Life Sci 2004;74:2975-2985. (Pubitemid 38402294)
39. Yoo J, Ghiassi M, Jirmanova L, Balliet AG, Hoffman B, Fornace AJ Jr, Liebermann DA, Bottinger EP, Roberts AB: Transforming growth factor-beta-induced apoptosis is mediated by Smad-dependent expression of GADD45b through p38 activation. J Biol Chem 2003;278:43001-43007. (Pubitemid 37345913)
40. Takekawa M, Tatebayashi K, Itoh F, Adachi M, Imai K, Saito H: Smad-dependent GADD45beta expression mediates delayed activation of p38 MAP kinase by TGF-beta. EMBO J 2002;21:6473-6482. (Pubitemid 35448425)
41. Major MB, Jones DA: Identification of a gadd45beta 3 enhancer that mediates SMAD3-and SMAD4-dependent transcriptional induction by transforming growth factor beta. J Biol Chem 2004;279:5278-5287. (Pubitemid 38220548)
42. Suzuki A, Kusakai G, Kishimoto A, Lu J, Ogura T, Esumi H: ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation. Oncogene 2003;22:6177-6182. (Pubitemid 37281647)
43. Suzuki A, Lu J, Kusakai G, Kishimoto A, Ogura T, Esumi H: ARK5 is a tumor invasion-associated factor downstream of Akt signaling. Mol Cell Biol 2004;24:3526-3535. (Pubitemid 38452091)
44. Klapholz-Brown Z, Walmsley GG, Nusse YM, Nusse R, Brown PO: Transcriptional program induced by Wnt protein in human fibroblasts suggests mechanisms for cell cooperativity in defining tissue microenvironments. PLoS One 2007;2:e945.
45. Marty MC, Alliot F, Rutin J, Fritz R, Trisler D, Pessac B: The myelin basic protein gene is expressed in differentiated blood cell lineages and in hemopoietic progenitors. Proc Natl Acad Sci USA 2002;99:8856-8861. (Pubitemid 34693648)
46. Forbes SJ, Russo FP, Rey V, Burra P, Rugge M, Wright NA, Alison MR: A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004;126:955-963. (Pubitemid 38451166)
47. Wynn TA: Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210. (Pubitemid 351160157)
48. Pinzani M: Welcome to fibrogenesis & tissue repair. Fibrogenesis Tissue Repair 2008;1:1.
49. Hindocha S, McGrouther DA, Bayat A: Epidemiological evaluation of Dupuytrens disease incidence and prevalence rates in relation to etiology. Hand (NY) 2009;4:256-269.
50. Rehman S, Salway F, Stanley JK, Ollier WE, Day P, Bayat A: Molecular phenotypic descriptors of Dupuytrens disease defined using informatics analysis of the transcriptome. J Hand Surg Am 2008;33:359-372. (Pubitemid 351384747)
51. Al-Qattan MM: Factors in the pathogenesis of Dupuytrens contracture. J Hand Surg Am 2006;31:1527-1534.
52. Suzuki A, Kusakai G, Kishimoto A, Lu J, Ogura T, Lavin MF, Esumi H: Identification of a novel protein kinase mediating Akt survival signaling to the ATM protein. J Biol Chem 2003;278:48-53. (Pubitemid 36043542)
53. Bujor AM, Pannu J, Bu S, Smith EA, Muise-Helmericks RC, Trojanowska M: Akt blockade downregulates collagen and upregulates MMP1 in human dermal fibroblasts. J Invest Dermatol 2008;128:1906-1914. (Pubitemid 352001221)
54. Hu Y, Peng J, Feng D, Chu L, Li X, Jin Z, Lin Z, Zeng Q: Role of extracellular signal-regulated kinase, p38 kinase, and activator protein-1 in transforming growth factor-beta1-induced alpha smooth muscle actin expression in human fetal lung fibroblasts in vitro. Lung 2006;184:33-42.
55. Meyer-Ter-Vehn T, Gebhardt S, Sebald W, Buttmann M, Grehn F, Schlunck G, Knaus P: p38 inhibitors prevent TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest Ophthalmol Vis Sci 2006;47:1500-1509. (Pubitemid 46780758)
56. Wang J, Fan J, Laschinger C, Arora PD, Kapus A, Seth A, McCulloch CA: Smooth muscle actin determines mechanical force-induced p38 activation. J Biol Chem 2005;280:7273-7284. (Pubitemid 40341285)
57. Kolosova I, Nethery D, Kern JA: Role of Smad2/3 and p38 MAP kinase in TGF-beta1-induced epithelialmesenchymal transition of pulmonary epithelial cells. J Cell Physiol 2011;226:1248-1254.
58. Matsuoka H, Arai T, Mori M, Goya S, Kida H, Morishita H, Fujiwara H, Tachibana I, Osaki T, Hayashi S: A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2002;283:L103-112. (Pubitemid 34764546)
59. Moran N: p38 kinase inhibitor approved for idiopathic pulmonary fibrosis. Nat Biotechnol 2011;29:301.
60. Nishida M, Okumura Y, Sato H, Hamaoka K: Delayed inhibition of p38 mitogen-activated protein kinase ameliorates renal fibrosis in obstructive nephropathy. Nephrol Dial Transplant 2008;23:2520-2524.
61. Li J, Campanale NV, Liang RJ, Deane JA, Bertram JF, Ricardo SD: Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-beta1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy. Am J Pathol 2006;169:1527-1540. (Pubitemid 351181986)
62. Zhang S, Weinheimer C, Courtois M, Kovacs A, Zhang CE, Cheng AM, Wang Y, Muslin AJ: The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J Clin Invest 2003;111:833-841. (Pubitemid 37074958)
63. Krause C, Kloen P, Ten Dijke P: Elevated transforming growth factor beta and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytrens disease fibroblasts. Fibrogenesis Tissue Repair 2011;4:14.
64. Ballif BA, Blenis J: Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 2001;12:397-408. (Pubitemid 32762689)
65. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, Davis RJ: Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995;270:7420-7426.
66. Edling CE, Hallberg B: c-Kit-a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol 2007;39:1995-1998. (Pubitemid 47376824)
67. Cabane C, Coldefy AS, Yeow K, Derijard B: The p38 pathway regulates Akt both at the protein and transcriptional activation levels during myogenesis. Cell Signal 2004;16:1405-1415. (Pubitemid 39277505)
68. Barth PJ, Schenck Zu Schweinsberg T, Ramaswamy A, Moll R: CD34+ fibrocytes, alpha-smooth muscle antigen-positive myofibroblasts, and CD117 expression in the stroma of invasive squamous cell carcinomas of the oral cavity, pharynx, and larynx. Virchows Arch 2004;444:231-234. (Pubitemid 38446434)
69. Hagood JS, Prabhakaran P, Kumbla P, Salazar L, MacEwen MW, Barker TH, Ortiz LA, Schoeb T, Siegal GP, Alexander CB, Pardo A, Selman M: Loss of fibroblast Thy-1 expression correlates with lung fibrogenesis. Am J Pathol 2005;167:365-379. (Pubitemid 43026094)
70. Hindocha S, Iqbal SA, Farhatullah S, Paus R, Bayat A: Characterization of stem cells in Dupuytrens disease. Br J Surg 2011;98:308-315.
71. Iqbal SA, Manning C, Syed F, Kolluru V, Hayton M, Watson S, Bayat A: Identification of mesenchymal stem cells in perinodular fat and skin in Dupuytrens disease: a potential source of myofibroblasts with implications for pathogenesis and therapy. Stem Cells Dev 2012;21:609-622.
72. Chang HY, Chi JT, Dudoit S, Bondre C, Van De Rijn M, Botstein D, Brown PO: Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA 2002;99:12877-12882.